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A total of 227 patients (mean age 41.3 years, 52% females) with at least one second-degree superﬁcial cutaneous burn of thermal
origin of a smallest transverse diameter ≥20mm and a largest transverse diameter ≤90mm were randomised to receive the topical
application of aqueous extract of Triticum vulgare (Fitostimoline) in two diﬀerent forms (soaked gauzes and cream) or catalase of
horse origin in form of gel (Citrizan Gel), given up to healing or to a maximum of 20 days. The rate of lesion healing at end of
study was signiﬁcantly higher in patients treated with Fitostimoline (gauzes 97.3%, cream 91.5%) than in those receiving catalase
(84.5%).ThepooledFitostimolinegroupswerealsosigniﬁcantlymoreeﬀective thancatalasegelinreducingtotalsymptomsscore,
painatmedication,painatrest,andburningatendofstudy.BothformulationsofFitostimolineandcatalasegelwerewelltolerated
in terms of adverse eﬀects in the site of application.
1.Introduction
The primary objectives of the treatment of second-degree
superﬁcial cutaneous burns are the maintenance of a
microenvironment favourable for the cellular regeneration,
the removal of the necrotic tissues and the prevention
of bacterial proliferation, which interfere with the healing
processes [1]. The local treatment of lesions is targeted at
maintaining a wet microenvironment and at stimulating
the formation of a well-vascularised granulation tissue, and
the reepithelialisation of the lesion while counteracting the
development of microorganisms, which is able to delay
or prevent the biological phenomena of cicatrisation and
reepithelialisation [2].
A variety of topical measures that ensure the protection
of the burn and hence the anatomic-functional recovery
of the aﬀected skin are actually available; however, not all
of them have in their composition factors that are able to
stimulatethereparation[3].Irrespectivelyofthepreparation
used in the local management of burn, the opinion of
not proceeding with the replacement of the medication
for more than once daily, to interfere as less as possible
with the tissue reparation dynamic, is widely agreed [4]. In
standard conditions and in absence of complications, the
period of reepithelialisation of a medium-size second-degree
superﬁcial burn is approximately of two weeks [5].
The Fitostimoline in form of soaked gauzes and cream
are widely used from some decades in the treatment
of cutaneous lesions in which a stimulation of repairing
processes (e.g., ulcerative-dystrophic damages, burns, delay
in cicatrisation) is needed, and their place in therapy is well
recognised [6, 7]. The aqueous extract of Triticum vulgare,
the active ingredient of Fitostimoline-based products, deter-
mines a marked acceleration of tissutal repairing processes,
stimulates chemotaxis and the ﬁbroblastic maturation, and
signiﬁcantly increases the ﬁbroblastic index, which are
crucial points in the repairing processes [8]. These activities
ﬁnd an experimental conﬁrmation both in the accelerated
proteinsynthesisandintheenhancedabilityofcaptationand
incorporation of marked proline from tissues. Furthermore,
the presence of 2-phenoxy ethanol in the product ensures an
eﬃcient antiseptical action [9, 10].2 Dermatology Research and Practice
In this comparative study, two diﬀerent formulations
of Fitostimoline for topical use, that is, soaked gauzes
and cream, were tested in the treatment of second-degree
superﬁcial cutaneous burns of thermal origin. A topical
specialty indicated in the topical treatment of burns, sores
and ulcers, which contains catalase of horse origin, has been
chosen as reference drug.
2. Methods
2.1.PatientPopulation. Thestudyprotocolincludedpatients
of both sexes aged 18 to 70 years, presenting a second-
degree superﬁcial cutaneous burn of thermal origin started
no more than 36 hours earlier. To be eligible for the study,
thelesionwasrequiredtohaveasmallesttransversediameter
≥20mm and a largest transverse diameter ≤90mm (in the
case of multiple lesions, the largest lesion that satisﬁed the
inclusion criteria was taken into account). Patients with
any of the following conditions had to be excluded from
study participation: concomitant presence of third-degree
burns; multiple lesions with total involvement >10% of body
surface;burnslocalisedatthelevelofhead,neck,face,palmar
or plantar surfaces, genital areas, peri-oriﬁce zones, interdig-
ital zones; presence of other important medical conditions
(e.g., uncontrolled diabetes mellitus, severe hepatic or renal
insuﬃciency, obstructive chronic arteriopathies involving
the aﬀected area of the study lesion, uncontrolled arterial
hypertension, neoplastic diseases, or other concomitant
seriousinfections);treatmentwithantineoplastics,immuno-
suppressants, or corticosteroids; pregnant or breastfeeding
females, or females at risk of pregnancy.
2.2. Study Design and Treatments. The study plan included a
baseline visit, in which patients eligible for the study were
randomly assigned to receive one of the following three
treatments: Fitostimoline soaked gauzes (Fitostimoline garze
impregnate,FarmaceuticiDamorS.p.A.,Italy),Fitostimoline
cream (Fitostimoline crema, Farmaceutici Damor S.p.A.,
Italy), and equine catalase (Citrizan gel IDI Farmaceutici
S.p.A., Italy). Fitostimoline soaked gauzes were applied onto
the lesion previously deterged with sterile saline solution
and/or disinfected with H2O2; the medicated gauze was then
covered with a sterile gauze (and, possibly, with cotton wool
in the case of particularly secreting lesions) and bandaged.
If required by the lesion size, the medicated gauze could
be wound into itself. In the case that the roof of the bulla
was intact, it had not to be opened. In patients treated with
Fitostimoline cream or with catalase gel, 4gr. of cream were
uniformly distributed on a 10×10cm sterile gauze, and then
applied onto the lesion as for Fitostimoline gauzes. All the
study drugs were applied once daily, starting from the base-
line visit. When the burn dressing was replaced, any necrotic
or exudate material was removed using a clip or buﬀer
with saline solution. The surgical debridement could be per-
formed only by the Investigator at the clinic. Follow-up visits
were scheduled at 5-day intervals of therapy, for a maximal
observationalperiodof20daysandamaximumofﬁvevisits.
In the case of lesion healing prior to the ﬁnal visit and
whenever a premature treatment discontinuation occurred,
an early withdrawal visit was scheduled, if necessary. Treat-
ment with antineoplastics, immunosuppressants, corticos-
teroids (local or systemic), or local cicatrising agents was not
permitted.Antibioticswerepermittedwhennecessaryforthe
characteristics of the burn. The use of paracetamol (500mg
tablets) was also permitted for pain relief.
2.3.OutcomeMeasures. Thepercentreductionfrombaseline
in the largest cross-diameter of the burn after 10 days of
therapy was the primary eﬃcacy variable. The reduction
of the largest cross-diameter at the other time points, and
of the surface area of the lesion, was also measured. After
wound detersion, a ﬁlm of transparent and sterile synthetic
material was applied on the lesion, on which a second
sheet of transparent synthetic material was spread down;
the border of the lesion was traced on this sheet using an
indelible pen (printing). The reference points used for the
measurement of transversal diameters were then marked on
the lesion print border. A photocopy of the printing was
used for the computerized and centralised calculation of
the lesion perimeter and surface area: the Visitrak portable
digital system (Smith&Nephew, Milan, Italy) was used to
track the lesion sizes.
A related endpoint was disappearance (healing) of the
lesion, corresponding to 0 values of cross-diameter and
surface area, which was used to calculate the proportion of
patients healed and time to healing.
Signs (functional limitation due to pain; perilesional
erythema, oedema) and symptoms (burning, pain at rest,
pain at medication, itching) due to the lesion were measured
using a 5-point scale (0 to 4: absent, mild, moderate, severe,
very severe) to obtain a total symptoms score (TSS) ranging
from 0 (absence of symptoms) to 28 (maximal symptoms).
Other eﬃcacy variables included: clinical success at the last
visit (deﬁned as healing of the lesion or a reduction of at
least 50% of baseline TSS); the percent of reepithelialisation
(reported as ≤25%; >25% and ≤50%; >50% and ≤75%;
>75% and ≤95%; >95% of initial lesion); and the use of
relief paracetamol. The patient’s acceptance of study drug in
termsofeaseofuseandconveniencewasexpressedusinga4-
pointscale(0to3:poor,suﬃcient,good,verygood).Adverse
events were recorded at any time throughout the study.
2.4. Ethics. Informed consent was signed by all participants
prior to the start of any study-related procedure. The study
protocol was approved by the reference Ethic Committee of
each participating site.
2.5. Statistical Analysis. T h es a m p l es i z ew a sb a s e do na
hypothesis of equivalence between the three treatments in
the primary eﬃcacy variable. The percent reduction from
baseline to Day 10 in the largest burn diameter was expected
to be in a range of 65–85%, equivalent to 0.938 to 1.173
in the angular scale where the distribution was likely to
be approximately normal, and the standard deviation was
assumed to be around 0.30 in this scale. Once deﬁned
alpha = 0.05 two-sided and power = 0.80, 120 evaluable
patients in each arm were calculated to be required to ruleDermatology Research and Practice 3
out a clinically relevant diﬀerence of 10% or more (in
the original untransformed scale) in the primary endpoint
between Fitostimoline soaked gauzes and cream. The same
number of patients had to be enrolled in the catalase gel
arm, in order that the test power for comparison with the
combined Fitostimoline arms was 0.90.
The following populations were considered for data
analysis: safety, that is, all randomised patients who received
at least one application of study medication; intention-to-
treat (ITT), that is, all patients of the safety population who
did not violate major inclusion-exclusion criteria; eﬃcacy,
that is, all patients of the ITT population who were visited
at least once after the baseline visit; per protocol (PP), that
is, all patients of the eﬃcacy population who completed the
study without major violations of study procedures.
The primary analysis of eﬃcacy was performed on the
reduction (as percent of baseline) in the largest burn diam-
eter at Day 10 after angular (arcsine of square root) trans-
formation of data. Nonparametric methods (Kruskal-Wallis
and Mann-Whitney tests, Hodges-Lehmann estimator of
location shift with Moses CIs) were used in the comparisons
between groups as the variable distribution departed from
normal (gaussian) even after transformation. The Mann-
Whitney test for independent groups was used to compare
Fitostimoline soaked gauzes with Fitostimoline cream. Since
the two formulations resulted as clinically equivalent (i.e.,
the 95% CI of the Hodges-Lehmann median diﬀerence was
entirely contained within an interval of ±10%), the data
from both Fitostimoline groups were pooled and compared
with catalase gel using Student’s t-the Mann-Whitney test.
The same methods described for the primary eﬃcacy
analysis were used for the reduction (as percent of baseline)
in the largest burn diameter at the other time points Day 5
and in the burn surface area at Day 5 and at Day 10. At Day
15 or at end of study the vast majority of the burns were
healed; therefore, the lesion status was analysed as a binary
variable (present/absent) by means of relative risk estimates
and Fisher’s exact test.
Percent of reepithelialisation, paracetamol consumption,
TSS (both as absolute values and as percent reduction from
baseline) and the scores of the individual signs and symp-
toms were compared between groups using nonparametric
tests (Kruskal-Wallis and Mann-Whitney).
The last observation was carried forward in the primary
eﬃcacy analysis and in all secondary analyses at ﬁxed
timepoints, that is, at Day 10 or at end of study.
Survival analysis methods (i.e., Kaplan-Meier estimates
and log rank test) were used to compare time to healing and
time to reepithelialisation >95%. Data concerning patient’s
opinion of acceptance were analysed using nonparametric
tests (Mann-Whitney and Kruskal-Wallis).
3. Results
3.1. Patient Disposition and Baseline Characteristics. At o t a l
of 227 patients (mean age 41.3 years, 52% females) were
enrolled at eight Italian hospital Units and were randomised
to receive the assigned treatment: 77 (33.9%) were included
in the Fitostimoline soaked gauzes group, 73 (32.2%) in the
Table 1: Demographic and lesion baseline characteristics in the
three groups (all patients enrolled). Entries are mean ± standard
deviation, unless otherwise stated.
Fitostimoline
soaked gauzes
Fitostimoline
cream
Catalase
gel
Sex, N (%) of
females 41 (53.2) 35 (47.9) 42 (54.5)
Age (years) 40.5 ±15.04 2 .8 ±14.04 0 .8 ±15.3
Weight (Kg) 69.7 ±13.27 3 .0 ±14.17 0 .1 ±13.5
Height (cm) 169 ±9 170 ± 9 169 ±9
Body mass index
(Kg/cm2) 24.3 ±4.02 5 .2 ±4.22 4 .4 ±3.9
Largest diameter
(cm) 65.9 ±20.86 6 .4 ±23.86 2 .8 ±20.0
Lesion surface area
(cm2) 25.8 ±16.22 8 .9 ±20.32 3 .1 ±15.0
Total symptoms
score 8.6 ±3.78 .2 ±3.59 .1 ±4.2
Fitostimoline cream group and 77 (33.9%) in the catalase
gel group. All randomised patients entered the safety and
ITT population. A total of 209 patients, 74 (96.1% of
randomised) in the Fitostimoline gauzes group, 69 (94.5%)
in the Fitostimoline cream group and 66 (85.7%) in the
catalase gel group, were treated up to Day 20 or healing,
while 8 patients among those visited at least once after
randomisation discontinued the treatment due to consent
withdrawal or unattended follow-up visits (1 in the Fitosti-
molinegauzesgroup,2intheFitostimolinecreamgroupand
5inthecatalasegelgroup).Nineteenpatientsincluded inthe
completer population, 1 in the Fitostimoline gauzes group, 7
in the Fitostimoline cream group and 11 in the catalase gel
group, had major protocol violations (mainly due to poor
compliance to treatment schedule) and were excluded from
the PP population.
Table 1 shows the demographic and main baseline char-
acteristics in the three groups. There were no substantial
diﬀerences between groups for any of the measured demo-
graphic parameters, for sizes of the lesions, and for TSS.
More than half of the burns (55.1% in the total population)
were caused by hot aqueous liquid or steam, and most
were located at the limbs, especially at the upper extremities
(58.1% overall).
3.2. Eﬃcacy. Figure 1 shows the largest burn diameter at any
time point in the eﬃcacy population (i.e., patients of the ITT
population who were visited at least once after the baseline)
and the comparisons between groups at Day 10 (primary
endpoint). The mean largest burn diameter progressively
decreased from baseline to end of study in all treatment
groups. There were no statistically signiﬁcant diﬀerences in
the overall comparison between groups between the two
Fitostimoline forms, and between the pooled Fitostimoline
groupsandcatalasegel,invaluesexpressedaspercentratioof
the baseline value. The diﬀerence between the Fitostimoline
soaked gauzes group and the Fitostimoline cream group4 Dermatology Research and Practice
Fitostimoline
gauzes
Fitostimoline
cream
Catalase
gel
P value
Overall comparison among groups
Fitostimoline gauzes-cream:
Fitostimoline pooled-catalase gel:
0
10
20
30
40
50
60
70
Baseline Day 5 Day 10 Day 15 Day 20
Fitostimoline gauzes
Fitostimoline cream
Catalase gel
Median (95% CI) 0.0 (0.0–20.4) 10.4 (0.0–33.3) 11.9 (0.0–35)
Mean (95% CI)a 13.7 (7–22.2) 19.6 (11–30) 20.8 (11.9–31.3)
.42‡
median (95% CI)b 0.0 (−5.7, 0.0) .3†
median (95% CI)b 0.0 (−0.9, 0.0) .41†
aBack transformation of values calculated on angular-transformed data
bHodges-Lehmann estimator and moses 95% CI
‡Kruskal-Wallis test
†Mann-Whitney test
Figure 1: Mean values of largest burn diameter (mm) during the study and results of comparisons between groups at Day 10 (eﬃcacy
population).
did not exceed 10% of baseline in either direction, which
proved that the two forms were essentially equivalent, as well
as this result was obtained in the comparison between the
pooled Fitostimoline groups and catalase gel. No statistically
signiﬁcant diﬀerences between groups were also observed at
Day 5.
The lesion surface area at any time point in the eﬃcacy
population and the comparisons between groups at Day 10
are shown in Figure 2. Mean lesion surface area progressively
decreased from baseline in all treatment groups. The com-
parisonsbetweengroupsdidnotshowstatisticallysigniﬁcant
diﬀerences at the time points examined between the two
Fitostimoline forms, and between the pooled Fitostimoline
groups and catalase gel, in values expressed as percent ratio
ofthebaselinevalue.Theresultsoflargestburndiameterand
lesion surface area in the PP population did not diﬀer from
those observed in the eﬃcacy population.
The analysis of lesion size (both the largest cross-
diameter and the surface area) at end of study in the eﬃcacy
population (Table 2) did not show signiﬁcant diﬀerences
between the two Fitostimoline groups in terms of lesion dis-
appearance (size 0 equivalent to complete healing), whereas
the risk of not achieving lesion disappearance was signiﬁ-
cantly lower in the pooled Fitostimoline groups compared
to the catalase gel group (P = .020, Fisher’s exact test).
Themedian time tohealingwas11daysin theFitostimo-
line gauzes group, 12 days in the Fitostimoline cream group
and 12 days in the catalase gel group, without signiﬁcant
diﬀerences between groups.
Clinical success (i.e., reepithelialisation >95% or TSS
reduction ≥50% from baseline) at the last visit in the eﬃcacy
population was obtained by 74 (98.7%) in the Fitostimoline
gauzes group, 69 (97.1%) in the Fitostimoline cream group
and 68 patients (95.8%) in the catalase gel group. In the
PP population, only one patient in the Fitostimoline cream
group (1.6%) and none in the other two arms were failures
according to this deﬁnition.
The results of reepithelialisation at Day 10 in the eﬃcacy
population are presented in Table 3. The proportion of
patients who achieved the various degrees of reepithelial-
isation was comparable in the three treatment groups: a
rate >75% of reepithelialisation was observed in 51 patients
(68.0%) in the Fitostimoline gauzes group, in 46 (64.8%)
in the Fitostimoline cream group and in 47 (66.2%) in the
catalase gel group. Although the proportion of patients with
>95% of reepithelialisation was higher in the Fitostimoline
cream group than in the other two groups, the comparisons
between groups did not show statistically signiﬁcant diﬀer-
ences, as well as there were no diﬀerences between groups at
end of study. The median time to reepithelialisation >95%Dermatology Research and Practice 5
Fitostimoline gauzes
Fitostimoline cream
Catalase gel
Overall comparison among groups
0
5
10
15
20
25
30
35
Baseline Day 5 Day 10 Day 15 Day 20
Fitostimoline
gauzes
Fitostimoline
cream
Catalase
gel
P value
Median (95% CI) 0.0 (0.0–3.9) 2.1 (0.0–10.5) 2.1 (0.0–14.3)
Mean (95% CI)a 6.6 (2.8–11.9) 10.9 (5.1–18.5) 11 (5.4–18.3)
Fitostimoline gauzes-cream: median (95% CI)b 0.0 (−1.4, 0.0) .24†
Fitostimoline pooled-catalase gel: median (95% CI)b 0.0 (−0.4, 0.0) .39†
aBack transformation of values calculated on angular-transformed data
bHodges-Lehmann estimator and moses 95% CI
‡Kruskal-Wallis test
†Mann-Whitney test
.35†
Figure 2: Mean values of lesion surface area (cm2) during the study and results of comparisons between groups at Day 10 (eﬃcacy
population).
Table 2: Lesion size and lesion disappearance (healing) at end of study in the eﬃcacy population.
Fitostimoline soaked gauzes Fitostimoline cream Catalase gel Fitostimoline
pooled
Largest cross-diameter#
mean (95% CI)a 0.1 (0.0–0.5) 0.4 (0.0–1.5) 2.3 (0.3–5.9) 0.2 (0.0–0.7)
Surface area#
mean (95% CI)a 0.1 (0.0–0.3) 0.2 (0.0–0.7) 1.6 (0.1–4.5) 0.1 (0.1–0.3)
N (%) of values = 0 71 (97.3) 65 (91.5) 60 (84.5) 136 (94.5)
N (%) of values > 0 2 (2.7) 6 (8.5) 11 (15.5) 8 (5.5)
Overall comparison among groups P = .024∗
Fitostimoline gauzes/cream RR (95% CI)b 0.32 (0.066–1.51) P = .16∗
Fitostimoline pooled/Catalase gel RR (95% CI)b 0.35 (0.15–0.84) P = .020∗
#As percent ratio of baseline value.
aBack transformation of values calculated on angular-transformed data.
bRelative risk of not achieving lesion disappearance (size 0).
∗Fisher’s exact test.
was 11 days in the Fitostimoline gauzes group, 12 days in
the Fitostimoline cream group and 11 days in the catalase gel
group.
Figure 3 shows the results of TSS at any time point in
the eﬃcacy population and the comparisons between groups
at end of study. A progressive decrease in mean TSS from
baseline to end of study was observed in all groups. The
comparisons between groups at end of study did not show
signiﬁcant diﬀerences between the two Fitostimoline groups,
while a statistically signiﬁcant diﬀerence was found in favour
of the pooled Fitostimoline groups compared to the catalase
gel group (P = .036, Mann-Whitney test).
In the analysis of TSS change from baseline expressed
in terms of increase, no change and diﬀerent degrees of6 Dermatology Research and Practice
Table 3: Reepithelialisation at Day 10 (eﬃcacy population).
Fitostimoline soaked gauzes Fitostimoline cream Catalase gel Fitostimoline
pooled
Range N (%) N (%) N (%) N (%)
>0% to 25% 3 (4.0) 4 (5.6) 5 (7.0) 7 (4.8)
>25% to 50% 11 (14.7) 6 (8.5) 13 (18.3) 17 (11.6)
>50% to 75% 10 (13.3) 15 (21.1) 6 (8.5) 25 (17.1)
>75% to 95% 9 (12.0) 11 (15.5) 13 (18.3) 20 (13.7)
>95% 42 (56.0) 35 (49.3) 34 (47.9) 77 (52.7)
Overall comparison among groups P = .64‡
Fitostimoline gauzes versus cream P = .62†
Fitostimoline pooled versus catalase
gel
P = .42†
‡Kruskal-Wallis test.
†Mann-Whitney test.
Fitostimoline gauzes
Fitostimoline cream
Catalase gel
0
1
2
3–4
5–7
8–10
52 (69.3)
5 (6.7)
5 (6.7)
1 (1.3)
50 (70.4)
6 (8.5)
10 (14.1)
4 (5.6)
41 (57.7)
9( 1 2 . 7 )
9( 1 2 . 7 )
4 (5.6)
1 (1.4)
1 (1.4) 4 (5.6)
3 (4.2)
Overall comparison among groups
Fitostimoline gauzes versus cream
Fitostimoline pooled versus catalase gel
0
1
2
3
4
5
6
7
8
9
10
Baseline Day 5 Day 10 Day 15 Day 20
Fitostimoline
gauzes
Fitostimoline
cream
Catalase
gel
P value
≥11
0 (0.0) 0 (0.0)
0 (0.0) 0 (0.0)
.11‡
.94†
.036†
‡Kruskal-Wallis test
†Mann-Whitney test
12 (16.0)
Figure 3: Mean values of total symptoms score during the study and results of comparisons between groups at end of study (eﬃcacy
population).
decrease (<50%, 50–99% and 100% regression), there were
no statistically signiﬁcant diﬀerences between groups at both
D a y1 0a n de n do fs t u d y .
The median time to TSS decrease ≥50% from baseline
was 6 days in the Fitostimoline gauzes group, 7 days in the
Fitostimoline cream group and 7 days in the catalase gel
group.
In the analysis of individual signs and symptoms (PP
population), a statistically signiﬁcant diﬀerence between the
pooled Fitostimoline groups and catalase gel was observedDermatology Research and Practice 7
for pain at medication (P = .021, Mann-Whitney test), pain
at rest (P = .007) and burning (P = .027) at end of study due
to a higher proportion of patients free of the symptom in the
pooled Fitostimoline groups (94.1% versus 83.6% for pain at
medication,100%versus94.5%forpainatrest,97.0%versus
89.1% for burning). There were no signiﬁcant diﬀerences in
the analysis of the other signs and symptoms, as well as in all
parameters between the two Fitostimoline forms.
The rate of patients who took paracetamol during the
study was comparable in the three treatment groups: 16.0%
intheFitostimolinegauzesgroup,11.3%intheFitostimoline
cream group and 15.5% in the catalase gel group. None
of patients in any group required surgical cleaning or
debridement of the lesion at any time during the study.
3.3. Acceptability. Among the patients in the eﬃcacy popu-
lation who expressed an opinion on treatment acceptability,
the proportion with very good or good opinion was higher
in the Fitostimoline soaked gauzes group (69 of 71, 97.2%)
and in the Fitostimoline cream group (63 of 66, 95.5%) than
in the catalase gel group (59 of 66, 89.4%), while a poor
opinion was reported by 4 patients (6.1%) in the catalase
group and by none in the two Fitostimoline groups. The
overall diﬀerence between the pooled Fitostimoline groups
and the catalase gel group was statistically signiﬁcant (P =
.006, Mann-Whitney test).
3.4. Safety. The rate of patients with adverse events was
higher in the catalase gel group (4 patients, 5.2%) than in
patients treated with Fitostimoline (only 1 patient—1.3%—
in the Fitostimoline gauzes group). The adverse event in the
patient in the Fitostimoline gauzes group consisted of local
signs of infection. In the catalase gel group, 3 adverse events
consisted of application site reactions (itching in 1 case,
burning upon application in 1 and itching and erythema in
1) and 1 adverse event consisted of abdominal pain.
4. Discussion
The dermatological application of the aqueous extract
of Triticum vulgare, that is, the active ingredient of
Fitostimoline-based products, is largely used in Italy from
approximately 20 years in the reparation of cutaneous
lesions and in all conditions requiring epithelial restoring.
The availability on the market of diﬀerent formulations of
Fitostimoline allows their use in diﬀerent aﬀections and
variables sizes of lesions, as well as according to the patients’
acceptance and preference. In a double-blind, randomised,
controlled study [11], the eﬃcacy of Fitostimoline gauzes in
the treatment of second-degree burns resulted to be signif-
icantly superior to that of placebo gauzes. Another recent
placebo-controlled study [12] that included 200 patients
with evidence of ulcerated dystrophic skin lesions and
delayed cicatritial healing showed a signiﬁcantly increased
rate of tissue repair and a rapid remission of clinical
symptoms in the Fitostimoline-treated group compared to
placebo. Fitostimoline in form of cream also proved to
be eﬀective in the treatment of gynaecological aﬀections
[13]. In this study we have compared the eﬀects of two
diﬀerent formulations of Fitostimoline (soaked gauzes and
cream) with a gel form of equine catalase (Citrizan) in the
topicaltreatmentofsecond-degreeburnsofsmalltomedium
size. Citrizan gel contains equine catalase and is indicated
in the topical treatment of burns, sores and ulcers. The
catalase is a haemoproteic enzyme that exerts a peroxidase
activity and also allows the release of molecules of oxygen
in the injured tissue. Burns and trauma are associated
with increased free radical production, which contribute to
the imbalance in endogenous antioxidant capacity and the
extension of primary lesions [14]. The role of antioxidants
as micronutrient in the regeneration and recovery of burn
lesions is well established [15]. It has been reported that
cellular oxidative stress is a critical step in burn-mediated
injury; therefore, antioxidant strategies designed to either
inhibit free radical formation in the necrobiotic tissue or
to scavenge free radicals may provide organ protection in
patients with burn injury [16]. For these reasons, we have
considered that equine catalase is a reliable and validated
activecomparatorin testing ofpharmacologicalagentsin the
reparation of second-degree burns.
The eﬃcacy results of this study showed that treatment
with both Fitostimoline formulations and catalase gel was
associated with a marked improvement from baseline of the
primary eﬃcacy variable (largest cross-diameter of the burn
at Day 10) in patients with second-degree superﬁcial cuta-
neousburnofthermalorigin, withoutstatisticallysigniﬁcant
diﬀerences in the comparison between Fitostimoline gauzes
and cream, and between pooled Fitostimoline groups and
catalase gel.
Changes from baseline of largest cross-diameter of the
burn at the other examined time points also did not
diﬀer between groups. All investigational study drugs also
produced a progressive and similar decrease from baseline of
the surface area of the lesion, without statistically signiﬁcant
diﬀerences between groups. However, at end of study the
rates of healing in the groups receiving Fitostimoline were
higher in the pooled Fitostimoline groups than in catalase
gel group. Although rates of healing of burn lesions and
of reepithelialisation >95% in the eﬃcacy population were
generally higher in the Fitostimoline soaked gauzes and
in the Fitostimoline pooled groups than in the catalase
gel group, the comparison between groups of time to
healing and time to reepithelialisation >95% did not show
statistically signiﬁcant diﬀerences. With this respect, it is
likely that the lower than scheduled sample of patients may
have limited the possibility to detect signiﬁcant diﬀerences
between groups.
Improvements in total symptoms score at end of study
were signiﬁcantly more marked in the Fitostimoline groups
than in the catalase gel group, as a result of a better outcome
in pain at medication, pain at rest and burning. Only
a minority of patients (which was similar in all groups)
required rescue paracetamol and none required surgical or
detersion procedures of the lesions. The safety results of
this study showed that both formulations of Fitostimoline
were at least as safe and well tolerated in terms of local
and general adverse eﬀects as the reference catalase gel
formulation. As conﬁrmation of the favourable eﬃcacy and8 Dermatology Research and Practice
tolerability proﬁle of Fitostimoline, a signiﬁcantly better
opinion on acceptability of treatment, which is mainly based
on subjective symptoms and tolerability, was reported by
patients treated with Fitostimoline formulations compared
to those treated with catalase gel.
Although some diﬀerences in favour of Fitostimoline
over catalase were observed after more than 10 days of
treatment, caution should be used in the interpretation of
these results. In this study, P-values for secondary analyses
should not be interpreted at the conventional signiﬁcance
level of .05 as they arise in a frame of repeated measures
and multiple testing. Furthermore, some of the patients who
did not heal or improve were not clinical failures at study
conclusion but were rather lost to observation, the disease
status at the time of discontinuation being carried forward
according to the planned analysis. Thus, the worse results
observed with catalase might be partly due to the higher rate
of study discontinuations in this group.
It should also be considered that, although measure-
ments of lesions were centralised in blinding condition,
the study used an open-label design due to the topical
administration of the three study medications, thus making
the double dummy design (use of the placebo of all
pharmaceutical forms) inapplicable, which cannot exclude
some degree of bias in secondary subjective endpoints (e.g.,
symptoms).
In conclusion, the results of this study have shown that
the topical application of Fitostimoline in soaked gauzes and
cream form is at least as eﬀective and safe as a gel form
containing equine catalase in the treatment of second-degree
superﬁcial cutaneous burn of thermal origin.
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